Format

Send to

Choose Destination
See comment in PubMed Commons below
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD000124. doi: 10.1002/14651858.CD000124.pub2.

Lobeline for smoking cessation.

Author information

1
Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. lindsay.stead@phc.ox.ac.uk

Abstract

BACKGROUND:

Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking.

OBJECTIVES:

The objective of this review was to assess the effects of lobeline on long term smoking cessation.

SEARCH METHODS:

We searched the Cochrane Tobacco Addiction Group trials register (most recent search December 2011).

SELECTION CRITERIA:

Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up.

DATA COLLECTION AND ANALYSIS:

We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up.

MAIN RESULTS:

We identified no trials meeting the full inclusion criteria including long term follow-up. One large trial failed to detect any effect on short-term abstinence.

AUTHORS' CONCLUSIONS:

There is no evidence available from long term trials that lobeline can aid smoking cessation, and the short-term evidence suggests there is no benefit.

Update of

PMID:
22336780
DOI:
10.1002/14651858.CD000124.pub2
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center